Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Enis H Ozmert

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
JHEP Reports : Innovation in Hepatology|April 8, 2026
Cell-SELEX identifies a DNA aptamer for highly selective in vivo siRNA delivery in cholangiocarcinomaBrandon A Wilbanks, Ayano Kabashima, Enis H Ozmert, et al.
Hepatology (Baltimore, Md.)|February 10, 2025
Aptamer-directed, nanovesicle-mediated targeting of undruggable molecules in preclinical cholangiocarcinoma modelsMincheng Yu, Jack W Sample, Irene K Yan, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Multiomics-driven discovery of predictive biomarkers and strategies to overcome resistance to SFK-YAP inhibition in cholangiocarcinomaHendrien Kuipers, Danielle M Carlson, Erik Jessen, et al.
Hepatology (Baltimore, Md.)|September 29, 2025
Multiomics combined with machine learning defines unique molecular subtypes of cholangiocarcinoma and identifies TNK1 as a therapeutic targetDong-Gi Mun, Erik Jessen, Jennifer L Tomlinson, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
JHEP Reports : Innovation in Hepatology|April 8, 2026
Cell-SELEX identifies a DNA aptamer for highly selective in vivo siRNA delivery in cholangiocarcinomaBrandon A Wilbanks, Ayano Kabashima, Enis H Ozmert, et al.
Hepatology (Baltimore, Md.)|February 10, 2025
Aptamer-directed, nanovesicle-mediated targeting of undruggable molecules in preclinical cholangiocarcinoma modelsMincheng Yu, Jack W Sample, Irene K Yan, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Multiomics-driven discovery of predictive biomarkers and strategies to overcome resistance to SFK-YAP inhibition in cholangiocarcinomaHendrien Kuipers, Danielle M Carlson, Erik Jessen, et al.
Hepatology (Baltimore, Md.)|September 29, 2025
Multiomics combined with machine learning defines unique molecular subtypes of cholangiocarcinoma and identifies TNK1 as a therapeutic targetDong-Gi Mun, Erik Jessen, Jennifer L Tomlinson, et al.
Pageof 1